Semax (AC-Semax-NH2) | 15 Mg Pen

Semax is a synthetic regulatory peptide derived from the ACTH (4–10) fragment and widely studied in neurotrophic and cognitive-signaling research. Across preclinical and selected human research contexts, it has been explored for its relationship to neurotrophin expression (including BDNF-related pathways), neurotransmission markers, and stress-response signaling under controlled experimental conditions. Information on this page is provided for scientific and educational context only and does not represent medical guidance or therapeutic claims.

Supports

1. Neurotrophic signaling context (BDNF/TrkB-related) tracked in neuronal and glial model systems.
2. Neuroplasticity and synaptic adaptation endpoints monitored in learning and stress paradigms.
3. Monoaminergic signaling context associated with dopamine/serotonin pathway markers in models.
4. Neuroinflammation and immune-response gene-expression readouts in neurobiology research settings.
5. Cellular resilience markers assessed in ischemia/oxidative-stress model frameworks.

Description

Semax is an ACTH-fragment–based synthetic peptide (commonly referenced as MEHFPGP) developed within the class of neuroactive regulatory peptides. It is frequently used in experimental neurobiology to map how neurotrophin signaling, neurotransmission balance, and inflammatory-marker patterns shift under stress, cognitive load, or injury-like conditions in controlled models.

In mechanistic literature, Semax is often discussed in connection with BDNF-related signaling and downstream pathways involved in synaptic function and adaptation. In parallel, multiple studies examine transcriptomic and immune-response readouts, positioning Semax as a probe compound in designs that evaluate neuroimmune crosstalk alongside behavioral or electrophysiologic endpoints.

Semax is presented here for controlled research and educational context only. It is not marketed as an approved therapeutic product, and reported observations can vary substantially by model, endpoints, timing, and study design.

Clinical Status

Semax has extensive preclinical and in vitro investigation and is also referenced in regional human research contexts, including studies that evaluate neurological recovery-associated endpoints. It is not presented here as an approved therapeutic product, and interpretation should remain study-specific and endpoint-driven.

Evidence type:
Human RCT ▣ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory approval ☐

Mechanism of Action

Mechanistic discussions around Semax commonly emphasize changes in neurotrophin signaling and gene-expression programs linked to neuronal survival and synaptic plasticity. Several experimental studies report BDNF-related expression changes in brain regions following Semax exposure, supporting its use in neuroplasticity-focused research frameworks.

Beyond neurotrophins, Semax has been evaluated in models of ischemic injury and stress exposure where transcriptomic signatures include immune-response and inflammation-related gene clusters. These molecular readouts are often paired with functional measures (behavioral, electrophysiologic, or recovery-associated endpoints) depending on the study design.

Benefits

• Upregulation Of Neurotrophic Factors:
  Semax has been studied for its ability to increase expression of brain-derived neurotrophic factor (BDNF) in both animal and human neurological research. BDNF plays a central role in synaptic plasticity, dendritic spine formation, and neuronal survival. Research demonstrates ↑ BDNF mRNA and protein levels in hippocampal regions following administration. This effect supports enhanced neuronal connectivity in experimental learning models. Neurotrophic activation is considered one of the core mechanisms underlying its cognitive research profile. Evidence type: Human clinical studies ✔ | Animal ▣.
• Enhanced Synaptic Plasticity And Memory Signaling:
  Clinical studies have evaluated Semax in cognitive impairment and attentional performance models. Improvements in memory recall and executive function scores have been documented in controlled settings. Mechanistically, ↑ CREB activation contributes to long-term potentiation processes within hippocampal circuits. Preclinical data show improved synaptic density under stress conditions. These findings support its role in experimental neuroplasticity enhancement.
• Modulation Of Dopamine And Serotonin Systems:
  Semax has been observed to influence monoaminergic neurotransmission, particularly dopamine and serotonin turnover. Laboratory studies indicate regulation of transporter activity and receptor sensitivity in cortical regions. This modulation contributes to balanced neurotransmitter signaling in stress-related research models. Improved attentional performance metrics have been associated with this pathway in human studies. Evidence type: Human ✔ | Animal ▣.
• Neuroprotection Under Ischemic And Oxidative Stress Conditions:
  In ischemic animal models, Semax administration has been associated with ↓ infarct volume and improved behavioral recovery scores. Research demonstrates ↓ glutamate excitotoxicity and ↓ oxidative stress biomarkers in neuronal tissue. Enhanced neuronal survival pathways have been documented through BDNF-mediated signaling. These effects position Semax within experimental stroke and neuroprotection research domains.
• Gene Expression Regulation And Anti-Inflammatory Modulation:
  Gene expression profiling studies show modulation of inflammatory cytokines and stress-response proteins following Semax exposure. Research indicates ↓ expression of certain pro-inflammatory mediators in brain tissue models. This regulatory influence contributes to a stabilized neuronal microenvironment. Evidence remains primarily preclinical with supporting clinical observations.
• Cognitive Resilience In Stress Models:
  Semax has been studied in models of acute and chronic stress exposure. Behavioral testing demonstrates improved performance compared to control groups under stress conditions. Mechanistic hypotheses suggest stabilization of monoamine signaling and neurotrophic pathways. These findings support inclusion in cognitive resilience research.
• Selective ACTH Fragment Without Cortisol Stimulation:
  Unlike full ACTH peptides, Semax does not significantly stimulate adrenal corticosteroid production. This selective activity allows neurological pathway modulation without systemic endocrine activation. Clinical endocrine markers confirm absence of significant cortisol elevation in controlled studies.
• High Bioavailability Through Subcutaneous Administration:
  Provided in a stabilized pre-mixed injection pen for SubQ administration, ensuring consistent systemic exposure in research protocols. Subcutaneous delivery supports reliable peptide absorption and simplifies laboratory handling. Each unit is freshly prepared and intended strictly for research use only.
  

Research Data

Stack Suggestions

In extended experimental designs, Semax is sometimes paired with:

• Selank (stress-response and neurotransmission-balance research contexts)
• DSIP (sleep/stress endpoint designs, where applicable)
• NAD+ (bioenergetic and cellular resilience marker panels in broader neurobiology studies)

Stacks discussed are for experimental design only, not safety/efficacy guidance.

Possible Side Effects

In research contexts, reported tolerability notes for Semax are generally described as mild and model-dependent. Where administered, observations may include transient local sensitivity or short-lived systemic effects. These notes are provided for general context only; they do not constitute medical guidance.

Local sensitivity: Temporary redness, swelling, or discomfort at the administration site has been reported in some settings.
Headache or fatigue: Transient effects have been noted anecdotally in certain protocols.
Dizziness or nausea: Occasional reports during early exposure windows in some settings.
Sensitivity reactions: Rare hypersensitivity-like responses are possible and warrant caution.

Scientific References

• Semax, an analogue of adrenocorticotropin (4–10), binds neurotrophin-related pathways and stimulates BDNF synthesis in astrocyte systems — In vitro / mechanistic
• The heptapeptide Semax stimulates BDNF expression in different areas of the rat brain in vivo — Animal
• Semax affects cognitive brain functions by modulating the hippocampal BDNF/TrkB system — Preclinical / mechanistic
• Semax affects expression of genes related to immune and vascular system function during rat brain focal ischemia — Animal / transcriptomics
• Semax affects expression of genes related to immune and vascular system function during rat brain focal ischemia (full text) — Animal / transcriptomics (PMC)
• Effect of Semax and the C-terminal peptide PGP on growth factor gene expression and receptors in experimental cerebral ischemia — Animal
• Semax and Pro-Gly-Pro activate transcription of neurotrophins and receptors after cerebral ischemia (full text) — Animal / gene expression (PMC)
• Semax regulates expression of immune response genes during ischemic brain injury in rats — Animal / gene expression
• Effectiveness of Semax in the acute period of hemispheric ischemic stroke (clinical study context) — Human clinical study
• The molecular aspects of Semax biological activity — Review

Cautions

• For educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.
• If you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.
• Discontinue use if sensitivity occurs.